Zio heart monitor results
![zio heart monitor results zio heart monitor results](http://www.frontiersin.org/files/Articles/135559/fphys-06-00149-HTML/image_m/fphys-06-00149-g002.jpg)
This is something that Zio can help to achieve, even during the ongoing pandemic, through accurate, remote monitoring.” The sooner an individual is diagnosed the sooner medical practitioners can deploy the best course of treatment. As with many heart conditions, the key to improving the outcome of AF – and therefore the associated risk of stroke – is through earlier and more accurate detection. When compared with implanted cardiac monitors, wearable ECG devices are noninvasive, less costly, more accessible, and can be self-applied by patients at home.Ĭommenting on the news, Justin Hall, GM and VP EMEA at iRhythm said, “AF is currently the leading independent risk factor of stroke, with more than 886,000 new people being diagnosed across Europe each year. Unlike handheld ECGs, watches, and blood pressure monitors, wearable continuous ECG devices can serve as both a screening tool and a diagnostic test, likely reducing the need for confirmatory testing. “The clinical validation that iRhythm has seen through its recent trials – mSToPS and SCREEN-AF – demonstrates that Zio proactively identifies arrhythmias based on risk factors, helping undiagnosed populations remotely monitor their symptoms and effectively seek treatment before more serious problems can occur.” “Approximately one-third of those who have AF are not aware that they have it, leaving them at a significantly elevated risk of stroke,” said Michael Coyle, CEO at iRhythm. Zio was found to be well tolerated and effective, and the results enabled some patients to receive anticoagulant therapy (anti-clotting medication) which has the potential to avert future strokes. The results have important implications for stroke prevention, especially as the prevalence of AF and AF-associated strokes is increasing with the aging of the population. The study results lend support for Zio as a screening tool for early detection of AF. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for protection against strokes.
#Zio heart monitor results trial
The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new “SCREEN-AF” study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology. LONDON-( BUSINESS WIRE)- iRhythm Technologies, Inc.